口服GPL-1R激动剂临床取得积极进展，歌礼制药股价大涨超28%
2月20日上午，歌礼制药股价盘中大涨超28%。消息面上，歌礼制药宣布小分子口服GPL-1R激动剂ASC30美国Ib期多剂量递增研究前两个队列取得积极期中结果。临床数据显示，在多剂量递增(MAD) 队列2中（每周剂量递增为2毫克、10毫克、20毫克和40毫克），每日一次服用ASC30口服片治疗28天后，肥胖症患者体重相对基线平均下降6.3%。－ 在MAD 队列1 中（每周剂量递增为2毫克、5毫克、10毫克和20毫克），每日一次服用ASC30口服片治疗28天后，肥胖症患者体重相对基线平均下降4.3%。（时代财经杜苏敏）
（文章来源：时代财经）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10